Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D organization to ...

Ratings for Alnylam Pharmaceuticals ALNY -1.28% Get Free Report were provided by 18 analysts in the past three months, ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

CAMBRIDGE, Mass., May 28, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals specializes in the development and commercialization of RNAi therapeutics for genetically defined diseases. The company has established itself as a leader in this ...

Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "RNAi Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's offering.

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore. 2025 Best Places to Work Join us on June 12th for our annual BPTW celebration.